248 related articles for article (PubMed ID: 23573240)
41. Valproate is protective against 6-OHDA-induced dopaminergic neurodegeneration in rodent midbrain: A potential role of BDNF up-regulation.
Lai CL; Lu CC; Lin HC; Sung YF; Wu YP; Hong JS; Peng GS
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):420-428. PubMed ID: 30031602
[TBL] [Abstract][Full Text] [Related]
42. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
[TBL] [Abstract][Full Text] [Related]
43. CART modulates the effects of levodopa in rat model of Parkinson's disease.
Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
[TBL] [Abstract][Full Text] [Related]
44. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
45. Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway.
Lou H; Jing X; Wei X; Shi H; Ren D; Zhang X
Neuropharmacology; 2014 Apr; 79():380-8. PubMed ID: 24333330
[TBL] [Abstract][Full Text] [Related]
46. Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease: involvement of antioxidative enzymes induction.
Wu CR; Tsai CW; Chang SW; Lin CY; Huang LC; Tsai CW
Chem Biol Interact; 2015 Jan; 225():40-6. PubMed ID: 25446857
[TBL] [Abstract][Full Text] [Related]
47. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Thornton E; Vink R
PLoS One; 2012; 7(4):e34138. PubMed ID: 22485158
[TBL] [Abstract][Full Text] [Related]
48. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
49. Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model.
Ozsoy O; Yildirim FB; Ogut E; Kaya Y; Tanriover G; Parlak H; Agar A; Aslan M
Free Radic Res; 2015; 49(8):1004-14. PubMed ID: 25791066
[TBL] [Abstract][Full Text] [Related]
50. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
51. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
52. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
Yuan WJ; Yasuhara T; Shingo T; Muraoka K; Agari T; Kameda M; Uozumi T; Tajiri N; Morimoto T; Jing M; Baba T; Wang F; Leung H; Matsui T; Miyoshi Y; Date I
BMC Neurosci; 2008 Aug; 9():75. PubMed ID: 18671880
[TBL] [Abstract][Full Text] [Related]
53. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
[TBL] [Abstract][Full Text] [Related]
54. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
55. Protective effect of Nrf2-ARE activator isolated from green perilla leaves on dopaminergic neuronal loss in a Parkinson's disease model.
Masaki Y; Izumi Y; Matsumura A; Akaike A; Kume T
Eur J Pharmacol; 2017 Mar; 798():26-34. PubMed ID: 28167258
[TBL] [Abstract][Full Text] [Related]
56. [The protective effect of ginsenoside Rg1 on dopaminergic neurons of substantia in the ovariectomized rat model of Parkinson's disease].
Xu L; Liu LX; Chen WF; Xie JX; Huang WX
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2008 Feb; 24(1):1-5. PubMed ID: 21141541
[TBL] [Abstract][Full Text] [Related]
57. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Paillé V; Brachet P; Damier P
Neuroreport; 2004 Mar; 15(3):561-4. PubMed ID: 15094523
[TBL] [Abstract][Full Text] [Related]
58. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
59. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.
Khan MM; Raza SS; Javed H; Ahmad A; Khan A; Islam F; Safhi MM; Islam F
Neurotox Res; 2012 Jul; 22(1):1-15. PubMed ID: 22194158
[TBL] [Abstract][Full Text] [Related]
60. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
